Stephen Devenport, MD
Family Medicine · Riverton, UTNPI 1093730467
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,197 of the $4,520 with a category attached, or 70.7%. 41 manufacturers reported payments, led by Modernatx, Inc. at 41.5% of the total. Reporting peaked in 2023 at $2,404 and has fallen 74.7% since, to $608 in 2025.
Across 162 payments — averaging $27.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$2K
- Astellas Pharma US Inc$325
- Boehringer Ingelheim$252
- AstraZeneca$207
- Abbott$195
- Novo Nordisk$172
- plus $1K from 35 others
Across 121 payments — averaging $10,567 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$440K
- Covis Pharma GmbH$225K
- Astrazeneca UK Limited$181K
- Astellas Pharma Global Development$160K
- AstraZeneca$158K
- BD$68K
- plus $47K from 2 others
What the payments were for
- Travel & lodging$1,32329%
- Food & beverage$3,19771%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 7 | $1,877 |
| Astellas Pharma US Inc | 17 | $325 |
| Boehringer Ingelheim | 13 | $252 |
| AstraZeneca | 15 | $207 |
| Abbott | 9 | $195 |
| Novo Nordisk | 12 | $172 |
| Ironshore Pharmaceuticals Inc. | 8 | $163 |
| AbbVie(2 entities) | 6 | $129 |
| GSK | 7 | $120 |
| Johnson & Johnson | 6 | $93 |
| Pfizer | 6 | $91 |
| Lilly USA, LLC | 6 | $86 |
| Supernus Pharmaceuticals, Inc. | 4 | $73 |
| Phathom Pharmaceuticals, Inc. | 4 | $60 |
| Sanofi-aventis U.S. LLC | 4 | $53 |
| Merck | 3 | $52 |
| Sobi, Inc | 3 | $47 |
| Exact Sciences | 3 | $42 |
| Lundbeck LLC | 3 | $42 |
| Amgen | 2 | $39 |
| Gilead | 2 | $32 |
| Bayer | 2 | $31 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Amarin Pharma, Inc. | 2 | $25 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Almatica Pharma LLC | 1 | $20 |
| Mylan Specialty L.p. | 1 | $19 |
| Cranial Technologies, Inc | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Grifols USA, LLC | 1 | $18 |
| Dexcom, Inc. | 1 | $18 |
| Therapeuticsmd, Inc. | 1 | $17 |
| Dynavax Technologies Corporation | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Organon | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Tris Pharma Inc | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
How this compares
$4,520 in reported general payments places this provider in the 80th percentile of 928 family medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 31 | $50,550 |
| JardianceEmpagliflozin | 34 | $43,477 |
| MounjaroTirzepatide | 35 | $41,811 |
| EliquisApixaban | 25 | $21,974 |
| XareltoRivaroxaban | 13 | $20,336 |
| MyrbetriqMirabegron | 15 | $17,618 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 17 | $8,961 |
| VascepaIcosapent Ethyl | 15 | $8,445 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $5,964 |
| Atorvastatin Calcium | 384 | $4,446 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $4,361 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $4,167 |
| Omeprazole | 181 | $3,447 |
| Levothyroxine Sodium | 237 | $2,730 |
| Metformin Hcl ErMetformin Hcl | 201 | $2,629 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Stiolto Respimat | $252 | $58,40163 claims |
| Novo NordiskOzempic | $172 | $50,55031 claims |
| Lilly USA, LLCMounjaro | $86 | $41,81135 claims |
| PfizerEliquis | $91 | $21,97425 claims |
| Johnson & JohnsonXarelto | $93 | $20,33613 claims |
| Astellas Pharma US IncMyrbetriq | $325 | $17,61815 claims |
| AbbVieSynthroid | $129 | $81019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 928 family medicine providers in Utah.
Other family medicine in Riverton
- Michael CobbleSandy$1.3M
- Thomas ClarkProvidence$332K
- Courtney NelsonLayton$190K
- David ButtersLayton$189K
- Scott EricksonBountiful$101K
- Mark CacciamaniSalt Lake City$43K
- Clint MowerLehi$41K
- Russell AndersonTooele$30K
- Kirk OdonnellSalt Lake City$23K
- John TemplemanProvo$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.